PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Pharmaceutics Dept., Faculty of Pharmacy, Helwan University, Cairo, Egypt. Electronic address: yasmin.abozeid@pharm.helwan.edu.eg.\', \'Pharmaceutical Chemistry Dept., Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University in Egypt, Cairo 12311, Egypt. Electronic address: nasser.saad@fue.edu.eg.\', \'Cellular and Molecular Immunology Research Centre, London Metropolitan University, 166-220 Holloway Road, London, N7 8DB, UK; National Heart and Lung Institute, Imperial College London, Norfolk Place, London W2 1PG UK. Electronic address: g.mclean@londonmet.ac.uk.\', \'Biochemistry Dept., Faculty of Pharmacy, Ain shams University, Cairo, 11566, Egypt. Electronic address: nadia_hamdy@pharma.asu.edu.eg.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0928-0987(20)30254-210.1016/j.ejps.2020.105465
?:doi
?:hasPublicationType
?:journal
  • European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
is ?:pmid of
?:pmid
?:pmid
  • 32668312
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all